FDA approves Pfizer's Lyrica CR for DPN, PHN pain

FDA approved Lyrica CR from Pfizer Inc. (NYSE:PFE) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN), but did not approve the drug for the management of fibromyalgia. Lyrica CR is a controlled-release formulation of pregabalin, a GABA receptor agonist.

An immediate-release formulation of Lyrica is approved in the U.S. to treat neuropathic pain associated with DPN or spinal cord injury. The drug is also approved to treat fibromyalgia and PHN, and as adjunctive therapy for adults with partial onset seizures...